Your AI-Trained Oncology Knowledge Connection!

Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted Therapies : Episode 11

Opinion

Video

February 11, 2025

Approaches to First-Line Treatment for Synovial Sarcoma

A panelist discusses how the standard first-line approach for synovial sarcoma typically involves anthracycline-based chemotherapy (often doxorubicin with ifosfamide) while considering factors such as patient age, performance status, and tumor burden to determine the specific regimen intensity and duration.

EP: 1.Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis

EP: 2.Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel

EP: 3.SPEARHEAD-1: Overview of Study Design, Key Efficacy, and Safety

EP: 4.Afami-cel Approval and Its Potential Influence on the Adoption of TCR Therapies

EP: 5.Key Differences in T-Cell Response Therapy vs CAR T Therapy

EP: 6.Optimal Timing for Introducing Afami-Cel Therapy in the Treatment Journey

EP: 7.Sequencing Strategies of Afami-Cel With Chemotherapy and Targeted Therapies

EP: 8.Addressing Potential Barriers to the Adoption of Afami-Cel Therapy

EP: 9.Best Practices for HLA and MAGE-A4 Testing

EP: 10.Diagnositc Feasibility: Liquid Biopsy vs Tissue Biopsy for Diagnostic Testing

Now Viewing

EP: 11.Approaches to First-Line Treatment for Synovial Sarcoma

EP: 12.Potential Impact of Afami-Cel Therapy on the Standard of Care for R/R Cases

EP: 13.Comparing Postinfusion Challenges in TCR Therapy and Standard-of-Care Regimens

EP: 14.Logistical Considerations for Delivering TCR Therapy to Patients

EP: 15.Comparing Afami-Cel Outcomes With Chemotherapy and Other Treatment Options

EP: 16.Future Perspectives on TCR Therapies for Sarcomas and Other Solid Tumors

Video content above is prompted by the following:

What is your typical approach to first-line treatment for synovial sarcoma?

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest Conference Coverage

Physical Functioning Measures May Predict Survival Outcomes, ICANS Risk With CAR T-Cell Therapy in NHL

First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC

Adjuvant CDK4/6 Inhibitors Lay a Solid Treatment Foundation in HR+, HER2– Breast Cancer

Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512